Walleye Capital
CATX icon

Walleye Capital’s Perspective Therapeutics CATX Stock Holding History

Walleye Capital’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$377K Buy
+110,656
New +$418K ﹤0.01% 2984
2026
Q1 		– Sell
-328,667
Closed -$904K – 4448
2025
Q4 		$904K Sell
328,667
-217,366
-40% -$620K ﹤0.01% 2519
2025
Q3 		$1.87M Buy
546,033
+358,630
+191% +$1.31M 0.01% 1632
2025
Q2 		$645K Buy
187,403
+148,013
+376% +$391K ﹤0.01% 2417
2025
Q1 		$83.9K Sell
39,390
-436,402
-92% -$1.31M ﹤0.01% 3682
2024
Q4 		$1.52M Buy
475,792
+457,675
+2,526% +$3.74M ﹤0.01% 2031
2024
Q3 		$242K Sell
18,117
-494,706
-96% -$6.58M ﹤0.01% 3855
2024
Q2 		$5.11M Buy
+512,823
New +$7.41M 0.01% 1266
2021
Q2 		– Sell
-2,423
Closed -$26K – 1355
2021
Q1 		$26K Buy
+2,423
New +$36.6K ﹤0.01% 1111

Other funds holding CATX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Walleye Capital's CATX Position: Q2 2026 in Review

Walleye Capital opened a new position in Perspective Therapeutics (CATX) in Q2 2026: 110,656 shares worth $377K. The stake represents ﹤0.01% of the portfolio and ranks #2984 among its holdings. This is a return to the name: Walleye Capital previously reported a position in CATX as recently as Q4 2025.

Walleye Capital first reported a position in CATX in Q1 2021 and has held it in 9 quarters since. The position peaked at $5.11M in Q2 2024. 132 funds tracked by Wall St. Rank hold CATX as of Q2 2026.

  • Walleye Capital held 110,656 shares of Perspective Therapeutics worth $377K as of Q2 2026.
  • Perspective Therapeutics was a new Walleye Capital position in Q2 2026.
  • Perspective Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #2984 holding.
  • Walleye Capital first reported a position in Perspective Therapeutics in Q1 2021 and has held it in 9 quarters since.
  • Walleye Capital's Perspective Therapeutics position peaked at $5.11M in Q2 2024.
  • 132 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.